Literature DB >> 26299221

Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009.

Todd M Brown1, Luqin Deng2, David J Becker2, Vera Bittner3, Emily B Levitan2, Robert S Rosenson4, Monika M Safford3, Paul Muntner2.   

Abstract

BACKGROUND: Few contemporary studies examine trends in recurrent coronary heart disease (CHD) events and mortality after acute myocardial infarction (AMI) and whether these trends vary by race or sex.
METHODS: We used data from the national 5% random sample of Medicare fee-for-service beneficiaries for 1999 to 2010. We included beneficiaries who experienced an AMI (International Classification of Disease [ICD] 9 410.xx, except 410.x2) between January 1, 2001, and December 31, 2009. Each beneficiary's first AMI was included as their index event. Outcomes included all-cause mortality, recurrent AMI, and recurrent CHD events during the 365days after discharge for the index AMI. To examine secular trends, we pooled calendar years into 3 periods (2001-2003, 2004-2006, and 2007-2009).
RESULTS: Among 48,688 beneficiaries with index AMIs from 2001 to 2009, we observed decreases in the age-adjusted rates for mortality (-3.8% for each 3-year period, 95% CI -6.1% to -1.6%, P trend = .001), recurrent AMI (-15.0%, 95% CI -18.6% to -11.2%, P trend < .001), and recurrent CHD events (-11.1%, 95% CI -14.0% to -8.0%, P trend < .001) in the 365days after the index AMI. In 2007 to 2009, blacks had excess risk relative to whites for mortality and recurrent AMI (black/white incidence rate ratio of 1.38 for mortality [95% CI 1.21-1.57] and 1.38 for recurrent AMI [95% CI 1.07-1.79]).
CONCLUSIONS: Despite overall favorable trends in lower mortality and recurrent events after AMI, efforts are needed to reduce racial disparities.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26299221     DOI: 10.1016/j.ahj.2015.04.027

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

1.  Secondary Prevention in Younger vs. Older Coronary Heart Disease Patients-Insights from the German Subset of the EUROASPIRE IV Survey.

Authors:  Martin Wagner; Götz Gelbrich; Julia Kircher; Kornelia Kotseva; David Wood; Caroline Morbach; Rainer Leyh; Georg Ertl; Wolfgang Karmann; Stefan Störk; Peter U Heuschmann
Journal:  Int J Behav Med       Date:  2018-06

Review 2.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

3.  Development of algorithms for identifying fatal cardiovascular disease in Medicare claims.

Authors:  Fenglong Xie; Lisandro D Colantonio; Jeffrey R Curtis; Meredith L Kilgore; Emily B Levitan; Keri L Monda; Monika M Safford; Ben Taylor; Mark Woodward; Paul Muntner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-03-14       Impact factor: 2.890

4.  Cardiovascular Disease Events and Mortality After Myocardial Infarction Among Black and White Adults: REGARDS Study.

Authors:  J Walker Blackston; Monika M Safford; Matthew T Mefford; Elizabeth Freeze; George Howard; Virginia J Howard; David C Naftel; Todd M Brown; Emily B Levitan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-12-11

5.  Fasa Registry on Acute Myocardial Infarction (FaRMI): Feasibility Study and Pilot Phase Results.

Authors:  Ehsan Bahramali; Alireza Askari; Habib Zakeri; Mojtaba Farjam; Azizallah Dehghan; Kazem Zendehdel
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

6.  Glycated hemoglobin level is an independent predictor of major adverse cardiac events after nonfatal acute myocardial infarction in nondiabetic patients: A retrospective observational study.

Authors:  Chin-Lan Chen; David H-T Yen; Chin-Sheng Lin; Shih-Hung Tsai; Sy-Jou Chen; Wayne H-H Sheu; Chin-Wang Hsu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

7.  Taurine Alleviates Sympathetic Innervation by Inhibiting NLRP3 Inflammasome in Postinfarcted Rats.

Authors:  Cheng-Che Lee; Wei-Ting Chen; Syue-Yi Chen; Tsung-Ming Lee
Journal:  J Cardiovasc Pharmacol       Date:  2021-04-15       Impact factor: 3.105

8.  Association Between Subsequent Hospitalizations and Recurrent Acute Myocardial Infarction Within 1 Year After Acute Myocardial Infarction.

Authors:  Yun Wang; Erica Leifheit; Sharon-Lise T Normand; Harlan M Krumholz
Journal:  J Am Heart Assoc       Date:  2020-03-14       Impact factor: 5.501

9.  Mobile Technology Utilization Among Patients From Diverse Cultural and Linguistic Backgrounds Attending Cardiac Rehabilitation in Australia: Descriptive, Case-Matched Comparative Study.

Authors:  Ling Zhang; Ding Ding; Lis Neubeck; Patrick Gallagher; Glenn Paull; Yan Gao; Robyn Gallagher
Journal:  JMIR Cardio       Date:  2018-06-26

10.  Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry.

Authors:  Oras A Alabas; Chris P Gale; Marlous Hall; Mark J Rutherford; Karolina Szummer; Sofia Sederholm Lawesson; Joakim Alfredsson; Bertil Lindahl; Tomas Jernberg
Journal:  J Am Heart Assoc       Date:  2017-12-14       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.